AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Transgene Initiates Two Phase II Trials In Breast, Lung Cancer.(Brief Article)
2002 FEB 13 - (NewsRx.com & NewsRx.net) -- Transgene (TRGNY, TRANSGENE) has initiated two Phase II clinical trials of its immunotherapeutic MVA-Muc1-IL2 vaccine candidate, one for the treatment of lung cancer, the second for the treatment of breast cancer. The clinical trials will be conducted in several centers located in Switzerland, France and Belgium.
Transgene's MVA-Muc1-IL2 product candidate uses a highly attenuated MVA vaccinia virus vector to express the Muc1 tumor-associated antigen found in most adenocarcinoma, and the cytokine interleukin-2 (IL-2) to stimulate specific T-cell responses. Phase I clinical trials of the product candidate, conducted in the United States and Europe, involved patients with various carcinomas. Those clinical trials demonstrated a positive safety and tolerance profile of MVA-Muc1-IL2, and provided evidence of immune response in some patients.
The purpose of treating lung and breast cancer patients with MVA-Muc1-IL2 is to induce an efficient immune response to the expression of the Muc1 antigen in order to produce a strong antitumor effect as demonstrated in earlier animal studies. The Muc1 antigen is expressed in more than 90% of breast cancers, in more than 60% of lung cancers, and in most secretory epithelial cell cancers.
"There is a need for novel approaches, such as our immunotherapy program to treat diseases like lung or breast cancer, where prognosis is poor despite progress made in the current treatments. We believe that our MVA-Muc1-IL2 vaccine candidate can be used alone or, in some cases, in combination with standard therapies, to treat these cancers and others," said Gilles Belanger, chief executive officer of Transgene. "We have made tremendous efforts to maintain our schedule for initiating Phase II clinical trials and are pleased to be conducting four clinical trials with our MVA-Muc1-IL2 and MVA-HPV-IL2 product candidates."
In 2001, Transgene was issued U.S. patents 6,203,795 and 6,328,956, both titled ...
- Transgene Initiates Two Phase II Clinical Trials With Its MVA-Muc1-IL2 Product...
- Press release article from: PR Newswire January 23, 2002 700+ words
...its immunotherapeutic MVA-Muc1-IL2 vaccine...for the treatment of lung cancer, the second for the...Belgium. Transgene's MVA-Muc1-IL2 product...381, covering its MVA-Muc1-IL2 product...for the treatment of lung cancer Lung cancer causes more...
- Transgene Reports Positive Interim Phase II Data from MVA-Muc1-IL2 Cancer...
- Press release article from: PR Newswire February 9, 2004 700+ words
...preliminary analysis of the lung cancer trial of MVA-Muc1-IL2 in combination...Lung Cancer The lung cancer trial is evaluating...subcutaneous injections of MVA-Muc1-IL2 in patients...advanced non-small cell lung cancer (stage IIIb and IV...
- Transgene Presents Data on MVA-MUC1-IL2 Cancer Vaccine at ASCO and ASGT Annual...
- Press release article from: PR Newswire June 8, 2004 700+ words
...clinical trials with its MVA-Muc1- IL2 therapeutic...phase II trial in lung cancer were presented on...Non-small-cell lung cancer The current phase...subcutaneous injections of MVA-Muc1-IL2 at a...non-small-cell lung cancer (stage IIIB or IV...
- Phase II Clinical Trials Initiated With Immunotherapeutic For Lung and Breast...
- Newspaper article from: Immunotherapy Weekly February 20, 2002 700+ words
...its immunotherapeutic MVA-Muc1-IL2 vaccine...for the treatment of lung cancer, the second for the...MVA-Muc1-IL2 and MVA-HPV-IL2 product candidates...for the treatment of lung cancer</b> Transgene...subcutaneous injections of MVA-Muc1-IL2 as a single...
- Poly-MVA[R] and prostate health: Shari Lieberman PhD, CNS, FACN discusses...
- Magazine article from: Townsend Letter: The Examiner of Alternative Medicine August 1, 2006 700+ words
...toxic cancer modalities. Poly-MVA[R] is a novel formula that...acetylcysteine. The initials MVA stand for minerals, vitamins...that the LAPd found in Poly-MVA may have a role to play in the...including prostate cancer and lung cancer. Recently, we had the opportunity...
- Poly-MVA.(cancer cells)
- Magazine article from: Townsend Letter for Doctors and Patients Klotter, Jule July 1, 2005 700+ words
...of these complexes is Poly-MVA, a nutritional supplement that...Health Publications' Poly-MVA by Robert D. Milne, MD, and...with a significant amount of lung cancer. High doses of LAPd in such...AMAS test, and that Poly-MVA may act as a paramagnetic contrast...
- Transgene Initiates Two Phase II Trials In Breast, Lung Cancer.(Brief Article)
- Newspaper article from: Cancer Weekly February 12, 2002 700+ words
...its immunotherapeutic MVA-Muc1-IL2 vaccine...for the treatment of lung cancer, the second for the...Belgium. Transgene's MVA-Muc1-IL2 product...381, covering its MVA-Muc1-IL2 product...any cause is related to lung cancer. Although some progress...
- Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb...
- Press release article from: PR Newswire January 10, 2008 700+ words
...evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first...patients with advanced non-small cell lung cancer (NSCLC). This on-going trial is...About TG4010 cancer vaccine TG4010 (MVA-MUC1-IL2) uses the Modified Vaccinia...